Heart of Darkness: The Downside of Trastuzumab
- 1 September 2006
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (25) , 4056-4058
- https://doi.org/10.1200/jco.2006.07.5143
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II TrialJournal of Clinical Oncology, 2006
- Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host DiseaseJournal of Clinical Oncology, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical TreatmentJournal of Clinical Oncology, 2005
- Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31Journal of Clinical Oncology, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast CancerJournal of Clinical Oncology, 2005
- Clinical Cardiac Tolerability of TrastuzumabJournal of Clinical Oncology, 2004
- Docetaxel in ovarian cancer: Phase III perspectives and future developmentSeminars in Oncology, 2002
- Trastuzumab and Breast CancerNew England Journal of Medicine, 2001